VivoSeq
Neurology

Duchenne Muscular Dystrophy (DMD)

4

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Duchenne Muscular Dystrophy (DMD) is an early-stage landscape with 4 programs across 3 companies. The most active players are Eli Lilly, Entrada Therapeutics, Inc., Larry W. Markham.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1E

Entrada Therapeutics, Inc.

2 programs

Phase 2L

Larry W. Markham

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Not yet recruiting2 · 50%
Recruiting2 · 50%

Clinical Trials

Trial Activity

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Not yet recruiting·EEntrada Therapeutics, Inc.·Phase 2·NCT07682129·80 enrolled
duCHennE caRdiomyopathy mItigation Sglt2 inHibitor
Recruiting·—·Phase 1·NCT07172971·10 enrolled
Evaluating Cardiac Function in Patients With Duchenne Muscular Dystrophy
Recruiting·VVanderbilt University Medical Center·N/A·NCT07674758·1,000 enrolled
Feasibility, Reliability, Clinical Validity and Sensitivity of Digital Outcomes to Monitor Upper Limb Function in Non-ambulant Patients With Genetically Confirmed Duchenne Muscular Dystrophy (DMD)
Not yet recruiting·Centre Hospitalier Universitaire de Liege·Preclinical·NCT07664124·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)